Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
• Age: 18 to 75 years.
• History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
• Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
• Diagnosis of Long COVID-19 based on WHO criteria.
• Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
• At least one symptom scoring between 1-7 on the C19-YRS.
• Stable medical condition: No recent hospitalization (past 3 months) due to acute illness.
• Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation